BioInvent International AB (publ)
BOVNFOTCHealthcare● Active
$6.63
+$3.34(+101.61%)
Market Cap$436282920
P/E Ratio—
52W High$6.63
52W Low$3.2886
BioInvent International AB (publ) (BOVNF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BOVNF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
-$0.20
Est. -$0.20 · +0.0%
Revenue
$0.00B
Est. $0.00B · +0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
✓ 1-Quarter EPS Beat Streak
BOVNF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 27, 2026 | -$0.20 | — | — | — | $0.00B | — |
| — Q2 FY2026 | Apr 29, 2026 | -$0.20 | -$0.20 | +0.0% | $0.00B | $0.00B | +0.0% |
| — Q1 FY2026 | Feb 26, 2026 | — | -$0.21 | — | $0.00B | — | — |
| — Q3 FY2025 | Aug 26, 2025 | — | $0.06 | — | $0.02B | — | — |
| — Q2 FY2025 | Apr 29, 2025 | — | -$1.78 | — | $0.02B | — | — |
| — Q1 FY2025 | Feb 27, 2025 | — | -$1.78 | — | $0.02B | — | — |
| — Q4 FY2024 | Oct 31, 2024 | — | -$1.48 | — | $0.01B | — | — |
| — Q3 FY2024 | Aug 29, 2024 | — | -$2.09 | — | $0.00B | — | — |
Q3 FY2026
Aug 27, 2026
EPS Actual
—
EPS Est.
-$0.20
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026
EPS Actual
-$0.20
EPS Est.
-$0.20
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2026
Feb 26, 2026
EPS Actual
-$0.21
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2025
Aug 26, 2025
EPS Actual
$0.06
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q2 FY2025
Apr 29, 2025
EPS Actual
-$1.78
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q1 FY2025
Feb 27, 2025
EPS Actual
-$1.78
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q4 FY2024
Oct 31, 2024
EPS Actual
-$1.48
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q3 FY2024
Aug 29, 2024
EPS Actual
-$2.09
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-1.66 | $-1.66 | $-1.66 | 1 |
| Q3 FY2026 | $-1.99 | $-1.99 | $-1.99 | 1 |
| Q2 FY2026 | $-1.91 | $-1.91 | $-1.91 | 1 |
| Q1 FY2026 | $-1.90 | $-1.90 | $-1.90 | 1 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $-1.05 | $-1.05 | $-1.05 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +0.0% | $3.29 | $3.29 | +0.00% |
| — Q1 FY2026 | Feb 26, 2026 | — | $3.29 | $3.29 | +0.00% |
| — Q3 FY2025 | Aug 26, 2025 | — | $3.29 | $3.29 | +0.00% |
| — Q2 FY2025 | Apr 29, 2025 | — | $4.70 | $4.70 | +0.00% |
| — Q1 FY2025 | Feb 27, 2025 | — | $4.70 | $4.70 | +0.00% |
| — Q4 FY2024 | Oct 31, 2024 | — | $4.70 | $4.70 | +0.00% |
| — Q3 FY2024 | Aug 29, 2024 | — | $4.70 | $4.70 | +0.00% |
| — Q2 FY2024 | Apr 24, 2024 | — | No price data | $4.70 | — |
Q2 FY2026+0.00%
Report Date
Apr 29, 2026
EPS Beat/Miss
+0.0%
Price Before
$3.29
Price After
$3.29
Q1 FY2026+0.00%
Report Date
Feb 26, 2026
EPS Beat/Miss
—
Price Before
$3.29
Price After
$3.29
Q3 FY2025+0.00%
Report Date
Aug 26, 2025
EPS Beat/Miss
—
Price Before
$3.29
Price After
$3.29
Q2 FY2025+0.00%
Report Date
Apr 29, 2025
EPS Beat/Miss
—
Price Before
$4.70
Price After
$4.70
Q1 FY2025+0.00%
Report Date
Feb 27, 2025
EPS Beat/Miss
—
Price Before
$4.70
Price After
$4.70
Q4 FY2024+0.00%
Report Date
Oct 31, 2024
EPS Beat/Miss
—
Price Before
$4.70
Price After
$4.70
Q3 FY2024+0.00%
Report Date
Aug 29, 2024
EPS Beat/Miss
—
Price Before
$4.70
Price After
$4.70
Q2 FY2024—
Report Date
Apr 24, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$4.70
Avg Beat Reaction+0.00%
Beat Rate1 / 8 quarters
Largest Move+0.00% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BOVNF ends December
BioInvent International AB (publ) (BOVNF) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $-0.20 (in line with the analyst consensus of $-0.20). The next BOVNF earnings date is expected around September 1, 2026.
Each quarter, investors track BOVNF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BOVNF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BOVNF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BOVNF earnings · 4 questionsBioInvent International AB (publ)'s next earnings report is expected around September 1, 2026. BOVNF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BOVNF historically reports after market close (AMC).
BOVNF earnings datewhen is BOVNF earningsBOVNF next earnings datewhen does BOVNF report earningsBOVNF earnings calendar
▸ Source: FMP · BioInvent International AB (publ) SEC filings · US GAAP · BioInvent International AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026